Literature DB >> 18756529

Protein misfolding inside cells: the case of huntingtin and Huntington's disease.

Danny M Hatters1.   

Abstract

Huntington's disease is one of the several neurodegenerative diseases caused by dominant mutations that expand the number of glutamine codons within an existing poly-glutamine (polyQ) repeat sequence of a gene. An expanded polyQ sequence in the huntingtin gene is known to cause the huntingtin protein to aggregate and form intracellular inclusions as disease progresses. However, the role that polyQ-induced aggregation plays in disease is yet to be fully determined. This review focuses on key questions remaining for how the expanded polyQ sequences affect the aggregation properties of the huntingtin protein and the corresponding effects on cellular machinery. The scope includes the technical challenges that remain for rigorously assessing the effects of aggregation on the cellular machinery. Copyright (c) 2008 IUBMB

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18756529     DOI: 10.1002/iub.111

Source DB:  PubMed          Journal:  IUBMB Life        ISSN: 1521-6543            Impact factor:   3.885


  26 in total

1.  Tracking protein aggregation and mislocalization in cells with flow cytometry.

Authors:  Yasmin M Ramdzan; Saskia Polling; Cheryl P Z Chia; Ivan H W Ng; Angelique R Ormsby; Nathan P Croft; Anthony W Purcell; Marie A Bogoyevitch; Dominic C H Ng; Paul A Gleeson; Danny M Hatters
Journal:  Nat Methods       Date:  2012-03-18       Impact factor: 28.547

2.  Tracking mutant huntingtin aggregation kinetics in cells reveals three major populations that include an invariant oligomer pool.

Authors:  Maya A Olshina; Lauren M Angley; Yasmin M Ramdzan; Jinwei Tang; Michael F Bailey; Andrew F Hill; Danny M Hatters
Journal:  J Biol Chem       Date:  2010-05-05       Impact factor: 5.157

3.  Loss of caveolin-1 expression in knock-in mouse model of Huntington's disease suppresses pathophysiology in vivo.

Authors:  Eugenia Trushina; Christie A Canaria; Do-Yup Lee; Cynthia T McMurray
Journal:  Hum Mol Genet       Date:  2013-09-10       Impact factor: 6.150

4.  Inhibition of Huntingtin Exon-1 Aggregation by the Molecular Tweezer CLR01.

Authors:  Tobias Vöpel; Kenny Bravo-Rodriguez; Sumit Mittal; Shivang Vachharajani; David Gnutt; Abhishek Sharma; Anne Steinhof; Oluwaseun Fatoba; Gisa Ellrichmann; Michael Nshanian; Christian Heid; Joseph A Loo; Frank-Gerrit Klärner; Thomas Schrader; Gal Bitan; Erich E Wanker; Simon Ebbinghaus; Elsa Sanchez-Garcia
Journal:  J Am Chem Soc       Date:  2017-04-13       Impact factor: 15.419

5.  Brief ampakine treatments slow the progression of Huntington's disease phenotypes in R6/2 mice.

Authors:  Danielle A Simmons; Rishi A Mehta; Julie C Lauterborn; Christine M Gall; Gary Lynch
Journal:  Neurobiol Dis       Date:  2010-10-23       Impact factor: 5.996

6.  Is type 2 diabetes an amyloidosis and does it really matter (to patients)?

Authors:  G J S Cooper; J F Aitken; S Zhang
Journal:  Diabetologia       Date:  2010-03-13       Impact factor: 10.122

7.  The Ubiquitin Receptor ADRM1 Modulates HAP40-Induced Proteasome Activity.

Authors:  Zih-Ning Huang; Lu-Shiun Her
Journal:  Mol Neurobiol       Date:  2016-11-05       Impact factor: 5.590

8.  The biological function of the Huntingtin protein and its relevance to Huntington's Disease pathology.

Authors:  Joost Schulte; J Troy Littleton
Journal:  Curr Trends Neurol       Date:  2011-01-01

9.  Inhibition of mitochondrial fragmentation diminishes Huntington's disease-associated neurodegeneration.

Authors:  Xing Guo; Marie-Helene Disatnik; Marie Monbureau; Mehrdad Shamloo; Daria Mochly-Rosen; Xin Qi
Journal:  J Clin Invest       Date:  2013-11-15       Impact factor: 14.808

Review 10.  Recent advances in our understanding of neurodegeneration.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2009-06-05       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.